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Abstract
Hepatocellular carcinoma (HCC) is one of the most 
common causes of cancer-related death worldwide. 
Liver cancer is generally related to hepatitis B or C 
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infection and cirrhosis. Usually, patients with HCC 
are asymptomatic and are diagnosed at late stages 
when surgical treatment is no longer suitable. Limited 
treatment options for patients with advanced HCC 
are a major concern. Therefore, there is an urge for 
finding novel therapies to treat HCC. Liver cancer is 
highly heterogeneous and involved deregulation of 
several signaling pathways. Wnt/β-catenin pathway is 
frequently upregulated in HCC and it is implicated in 
maintenance of tumor initiating cells, drug resistance, 
tumor progression, and metastasis. A great effort in 
developing selective drugs to target components of the 
β-catenin pathway with anticancer activity is underway 
but only a few of them have reached phase Ⅰ clinical 
trials. We aim to review the role of β-catenin pathway 
on hepatocarcinogenesis and liver cancer stem cell 
maintenance. We also evaluated the use of small 
molecules targeting the Wnt/β-catenin pathway with 
potential application for treatment of HCC. 
Key words: Hepatocellular carcinoma; Wnt/β-catenin 
pathway; Liver cancer stem cells; Molecular therapy
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Several signaling pathways have been 
described to be deregulated in hepatocellular carcinoma 
(HCC). There are limited treatment options currently 
available in advanced liver cancer. Wnt/β-catenin 
pathway is frequently upregulated and has emerged as 
an alternative target in HCC. Our group has studied the 
role of β-catenin inhibition alone and in combination 
in HCC treatment. In this review we summarized 
the existing literature on the importance of Wnt/
β-catenin pathway on hepatocarcinogenesis, tumor 
progression, relationship with liver stem cells and cancer 
therapeutics.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common 
primary malignancy of the liver and the third most 
common cause of cancer-related deaths worldwide[1]. 
Its prevalence differs greatly by geographical location 
reflecting variations in the main risk factors. Most 
cases of HCC (80%) arise in the Asian-Pacific and 
sub-Saharan African regions where the prevailing risk 
factor is chronic hepatitis B virus (HBV) infection. In 
Western countries, the incidence has been rapidly 
increasing due to infection with hepatitis C virus (HCV) 
and alcohol[2].
Early HCC is asymptomatic and a majority of the 
patients are diagnosed when the disease is advanced 
and they are no longer candidates for surgical curative 
therapy. Resection remains the treatment of choice for 
patients with well-preserved liver function; however, 
it is still associated with a high risk of post-operative 
complications and tumor recurrence. Among patients 
who have underlying cirrhosis, liver transplantation 
is considered the best therapeutic option in selected 
candidates but its use is limited by the shortage of 
potential donors. Other alternative treatments for 
HCC include radio-frequency ablation, microwave 
ablation, transcatheter arterial chemoembolization, 
radio embolization, and molecular targeted therapies/
chemotherapy[2,3]. 
In past decades, there have been significant efforts 
from different groups to develop compounds to treat 
HCC. Sorafenib, a multikinase inhibitor, has been 
found to be active against HCC in several pre-clinical 
and clinical studies, slowing tumor progression and 
improving survival in patients with advanced HCC. 
It is the drug of choice in patients with advanced 
HCC that are unsuitable for other types of surgical, 
ablative and embolization interventions[4]. Tumor 
recurrence remains a strong limitation to any of the 
HCC treatments, hence understanding the molecular 
biology of HCC is crucial for the development of novel 
therapies. 
Numerous signaling pathways have been found to 
be deregulated in HCC including the Ras/Raf/MAPK, 
PI3K/mTOR, Notch, HGF/c-MET, IGF, VEGF, PDGF, and 
Wnt/β-catenin pathway[4-6]. Wnt signaling is involved in 
several physiological and physio-pathological processes 
during embryonic development and carcinogenesis[7,8]. 
Wnt/β-catenin signaling plays a critical role in liver 
development, liver regeneration and liver zonation 
which is required for spatial separation of the diverse 
metabolic functions performed in the liver[7]. Aberrant 
activation of this signaling pathway has been found 
in several tumors from different origin. In HCC, 
β-catenin accumulation has been observed in about 
10%-50% of tumors, and has been correlated with 
tumor progression and poor prognosis[9-11]. Based on 
these observations, interfering with the Wnt/β-catenin 
pathway might be a tempting target for liver cancer 
therapy. Several compounds have been developed 
to target this pathway and their potential in clinical 
trials is under study. Our group recently investigated 
the ability of FH-535, a dual inhibitor of β-catenin 
pathway and the peroxisome proliferator-activated 
receptor (PPAR), to inhibit HCC and liver cancer stem 
cells (LCSC) growth in vitro and its effectivity in a 
combination therapy with sorafenib[12,13].
The aim of this article is to review the literature 
on the role of Wnt/β-catenin signaling pathway as a 
potential molecular-targeted therapy in HCC.
WNT/β-CATENIN SIGNALING PATHWAY
The Wnt pathway diversifies into two main branches, 
canonical or β-catenin-dependent and non-canonical or 
β-catenin-independent. The canonical pathway involves 
three complexes: the ligand/receptor cell membrane 
complex, the cytosol β-catenin destruction complex, 
and the nuclear β-catenin/TCF/LEF transcription 
complex[14,15]. Wnt protein can bind to the heterodimeric 
receptor complex of a frizzled (Fz) and a single trans-
membrane lipoprotein receptor-related protein (LPR) 
5 or 6 co-receptors. When Fz/LRP receptors are not 
engaged, β-catenin is clustered, phosphorylated and 
ubiquitin-labeled by the multiprotein “destruction 
complex” that includes the tumor suppressors axin 
and adenomatous polyposis coli (APC), the Ser/Thr 
kinases glycogen synthase kinase 3 (GSK-3) and casein 
kinase 1 (CK1), the protein phosphatase 2A, and the 
E3-ubiquitin ligase β-TrCP (Figure 1, right panel). Once 
phosphorylated, β-catenin is ubiquitinated and destroyed 
by the proteasome. Therefore, the destruction complex 
regulates the stability and availability of β-catenin, 
thus playing a key role in the modulation of the Wnt 
signaling cascade. Wnt/β-catenin signaling initiates 
by binding of the Wnt protein to the Fz/LPR receptor 
complex (Figure 1, left panel). As soon as Wnt binds 
Fz and LPR, the destruction complex is deactivated. As 
a consequence, non-phosphorylated active β-catenin 
accumulates in the cytoplasm and it translocates into 
the nucleus where it binds to the lymphoid enhancer 
factor/T-cell factor (LEF/TCF). This binding displaces the 
transcriptional inhibitor Groucho, and in a complex with 
TCF initiates transcription of target genes such as CD44, 
EpCAM, survivin, cyclin D1, glutamine synthetase, 
iNOS, and c-Myc, among others[7,8,16-19]. In normal 
cells, extracellular Wnt ligands can interact with a few 
secreted antagonists, including frizzled-related protein 
and Dickkopf family members, preventing the activation 
of this pathway.
The association of Wnt pathway and carcinogenesis 
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was first described in patients with APC, where 
β-Catenin pathway is altered[20,21]. Interestingly, many 
additional associations between components of this 
pathway and disease, including hepatocarcinogenesis, 
have been revealed over the last two decades. 
WNT/β-CATENIN ACTIvATION IN 
HEPATOCARCINOGENESIS
Aberrant activation of Wnt/β-Catenin signaling has 
been reported in a wide range of HCC patients. Nuclear 
accumulation of β-catenin is strongly associated 
with β-catenin mutations, a majority of which have 
been described to be missense mutations at exon 3, 
responsible for phosphorylation and destruction of 
β-catenin[22]. 
Mutations in β-catenin gene 1 (CTNNB1) have been 
reported in around 20%-40% of all HCC cases[6,23-26]. 
Cieply et al[27] compared the tumor features of HCC in 
the presence or absence of CTNNB1 gene mutations. 
Their results indicated a strong association between 
the presence of CTNNB1 mutations and increased 
tumor size, macrovascular and microvascular invasion, 
which supports the contribution of aberrant β-catenin 
signaling to tumor aggressiveness. The abnormal 
activity of β-catenin has been also linked with HCC in 
the setting of HCV and HBV infections. High incidence 
of CTNNB1 mutations in up to 40% of cases has been 
reported in patients with HCC and HCV infection. 
Previous studies have also correlated the presence of 
HCV core protein with increased expression of Wnt-1 
in hepatoma cells[7]. 
Lachenmayer et al[11] proposed a molecular 
classification of HCC based on Wnt-pathway aberrations 
in HCC into two groups: CTNNB1 molecular class and 
Wnt-TGFβ molecular class. The authors found that Wnt-
TGFβ class was associated with cytoplasmic β-catenin 
accumulation, vascular invasion, and an increased risk 
of early recurrence after surgical resection. A strong 
association between cytoplasmic β-catenin expression 
and poor histological differentiation, tumor size > 5 
cm in diameter, and decreased disease-free survival 
has previously been reported[28]. Inagawa et al[29] 
demonstrated poor prognosis in HCC patients with 
nuclear β-catenin accumulation in high grade HCC 
tumors. Nuclear β-catenin accumulation in HCC has 
also been associated to Ki67, suggesting that β-catenin 
promotes tumor proliferation and progression[30]. 
The link between Wnt/β-catenin signaling pathway 
and cell cycle seems to play a crucial role during 
the genesis and development of HCC. Wang et 
al[31] reported that suppressing β-catenin gene may 
induce the changes in cyclin B1 and cyclin C protein 
expression. Liu et al[32] showed that human zinc finger 
protein 191 is a potential regulator of the β-catenin 
transcription, found to be significantly overexpressed in 
human HCC specimens and associated with growth of 
human HCC cells. Mutations have also been reported in 
the components of the degradation complex of β-catenin 
including AXIN1 in around 3%-16% and AXIN2 in 
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Figure 1  Wnt-β-catenin signaling pathway. Binding of Wnt protein initiates a cascade, which results in activation of β-catenin, its accumulation in the cytoplasm 
and translocation into the nucleus to enhance the transcription of target genes (Left); When Fz/LRP receptors are not engaged, CK1 and GSK3B sequentially 
phosphorylate Axin-bound β-catenin. Consequently, β-catenin is ubiquitinated and targeted for rapid destruction by the proteasome (Right).
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Analyses of miRNA expression have shown the 
different level of expression of miR-122a, miR-125a, 
and miR-150 in HCC cells and normal human primary 
hepatocytes[48,49]. Augello et al[50] studied the expression 
of 664 mature miRNA in a cohort of 60 HCV-positive 
liver lesions and determined the genomic status of the 
miRNA chromosome 19 miRNA cluster (C19MC). Four 
miRNAs overexpressed in HCC belonged to C19MC 
and were significantly associated with microvascular 
invasion. Ji et al[51] found that the reduced expression 
of miR-26 correlated with the development of more 
aggressive forms of HCC. Interestingly, the same 
authors found that the expression of miR-26 is an 
independent predictor of survival in HCC patients. 
miRNA-181 has been shown to regulate the Wnt/
β-catenin signaling pathway in a positive feedback 
loop, promoting the stem cell-like features of HCC 
cells[52]. Overall, the exploration of the molecular link 
between Wnt/β-catenin and miRNAs could increase the 
understanding of the intricate molecular regulation in 
LCSCs, facilitating the design of effective therapeutic 
strategies. 
Targeting β-catenin pathway: Is there a role for 
combination therapy in HCC?
Sorafenib monotherapy is currently the standard of 
care for patients with advanced HCC[2,3]. However, in a 
double-blind, placebo-controlled trial, the median overall 
survival of patients on sorafenib group is prolonged by 
only 2.8 mo[3]. Therefore, there is a particular interest in 
the development of new and more effective strategies 
to treat HCC. Evidence from in vitro and in vivo studies 
indicates that combination therapy could be more 
effective. Our group has demonstrated additive and 
synergistic effect of targeting Ras/Raf/MAPK pathway 
in combination with other pathways important in 
HCC proliferation such as PI3K/AKT/mTOR and Wnt/
β-catenin[53]. 
Based on recent studies indicating the important 
role of Wnt/β-catenin signaling in the maintenance of 
CSCs, there has been increasing interest in developing 
new compounds to inhibit this pathway (Tables 1 and 
2). One of the first studies aimed at disrupting the 
interaction between β-catenin and TCF. About 7000 
natural compounds were screened using an enzyme-
linked immunosorbent assay[54]. Two fungal-derived 
compounds, PKF115-854 and CGP04909, showed 
the best results for their potency and specificity in 
antagonize the β-catenin-mediated cellular effects[54]. 
These compounds have been further tested as 
anticancer drugs for malignancies displaying frequent 
upregulation in the Wnt/β-catenin signaling such 
as human multiple myeloma[55], Acute Myelocytic 
Leukemia[56], Chronic Lymphocytic Leukemia[57] and 
HCC[58,59]. Two studies have assayed the therapeutic 
potential of CGP049090, PKF115-584 and PKF118-310 
in HCC. All three compounds showed dose-dependent 
cytotoxicity against HCC cells with relative lower cyto-
around 3% of all HCC cases[33]. 
Three other Wnt genes (Wnt3, Wnt4 and Wnt5A), 
and three FZD genes (FZD3, FZD6 and FZD7) have 
been identified to be up-regulated in 60%-90% of 
human HCCs and more than 50% of the surrounding 
pre-neoplastic liver tissues, suggesting that their 
overexpression may be an early event in hepatocar-
cinogenesis[34].
Wnt/β-catenin signaling pathway has also been 
found to contribute to the regulation of HCC angio-
genesis, infiltration, and metastasis through regulation 
of the expression of angiogenic factors such as MMP-2, 
MMP-9, VEGF-A, VEGF-C, and BFGF[35].
MOLECULAR MECHANISMS Of HCC
LCSC and β-catenin signaling 
Hepatocarcinogenesis is a complex process that so far 
has not been completely elucidated. The Cancer Stem 
Cells (CSCs) hypothesis postulates that tumors are 
comprised of a heterogeneous population of cells, which 
includes a minor group of cellls characterized by their 
capacity of continuous self-renewal and differentiation, 
long-lasting survival, and transplantability. It has 
been suggested that presence of LCSCs within the 
tumors could explain HCC heterogeneity, metastasis, 
recurrence, and chemotherapeutic resistance[36-39]. 
Different cell markers, including EpCAM, CD133, 
CD90, CD44, CD24, and CD13, have been used to 
identify the LCSC subpopulation. Such markers are 
heterogeneous in expression and represent cells of 
different origins. EpCAM, CD44, and CD133 are the 
most frequently used markers for the enrichment of 
tumor-initiating cells from primary human cancer[38-40]. 
Yamashita et al[41] published that isolated HCC EpCAM+ 
cells from alpha-fetoprotein positive HCC cases are 
LCSCs, in which activation of Wnt/β-catenin signaling is a 
major feature. Other reports suggest that pharmacologic 
targeting of β-catenin could inhibit proliferation and 
invasiveness capacity of LCSCs producing downregu-
lation of the expression of markers (CD44 and CD133) 
in vitro and in vivo[42].
Our group and others have studied LCSCs and 
differences in resistance patterns with HCC cell lines 
(Huh7, Hep3B, PLC) in vitro and in vivo by targeting 
the Wnt/β-catenin pathway[43-45]. Understanding the 
precise molecular basis of altered Wnt/β-catenin 
pathway should bring important advances in HCC 
biology with significant therapeutics associations. 
MicroRNAs regulation of β-catenin pathway in HCC 
Emerging evidence suggests the role of microRNAs 
(miRNAs) in the regulation of key biological properties 
of LCSCs[46]. During hepatocarcinogenesis miRNAs 
have been shown to have both tumor suppressive and 
oncogenic activity. Selected miRNAs such as miR-21, 
miR-224, miR-34a, miR-221/222, miR-106a, and 
miR-203, are upregulated in HCC[47]. 
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toxicity to normal hepatocytes. In a HepG2 xenograft 
model, these compounds inhibited tumor growth 
associated with apoptosis and reduced levels of 
TCF4/β-catenin target genes[58]. Yamashita et al[59] 
demonstrated that the epithelial cell adhesion molecule 
(EpCAM, a hepatic stem cell marker) is a direct trans-
criptional target of the Wnt/β-catenin pathway in HCC. 
EpCAM-expressing HCC were more sensitive to the 
β-catenin/TCF4 antagonists, CGP049090, PKF115-584 
and PKF118-310, than EpCAM-negative HCC.
Thorne et al[60] identified the FDA-approved drug 
Pyrvinium as an inhibitor of the Wnt signaling by 
enhancing the activity of the destruction complex 
though the binding to CK1 and selectively potentiating 
CK1α kinase activity. Whereas protein kinases have 
proven to be effective drug targets in cancer, the specific 
role of inhibitors of CK1 have yet to be completely 
elucidated. 
Other low molecular mass compounds such as 
XAV939 have been identified to prolong the half-life 
of Axin and promote β-Catenin degradation through 
inhibiting tankyrase[61-64]. 
Other strategy for attenuating the Wnt/β-catenin 
signaling pathway is by blocking the interaction 
between Fz receptors with their ligands. The effective 
interference of Fz and Wnt interaction has been 
achieved with monoclonal antibodies or with recom-
binant soluble fragment of Fz (sFz). OMP-18R5, is a 
novel monoclonal antibody that interacts with five Fz 
receptors to block canonical Wnt signaling. It has been 
used to inhibit the growth of several types of human 
cancers and has shown to be synergistic with other 
drugs such as taxol, irinotecan and gemcitabine[65]. 
Wei et al[66] found that a recombinant sFz7 peptide 
inhibited Wnt/β-Catenin signaling and decreased 
proliferation and tumorigenesis in some HCC cell lines. 
Nambotin et al[67] used small interfering peptides in 
HCC to block Fz7 function Wnt signaling and tumor 
progression. 
Chrysin, a naturally distributed flavonoid, has 
been described to inhibit proliferation and induce 
apoptosis in a variety of cancer cells[68]. Quan et al[42] 
demonstrated that a synthetic analogue of Chrysin, 
8-bromo-7-methoxychrysin, inhibited the stem cell-
like properties of CD133+ cells derived from MHCC97 
cell line in vivo and in vitro. They proposed that the 
mechanism may relate to a reduction levels of Akt and 
activation of GSK-3β[64]. 
Interestingly, some small molecules that inhibit the 
interaction between β-Catenin and CBP could induce 
cancer stem cells to differentiate, thereby eventually 
clearing the pool of cancer initiating cells. 
Delgado et al[18] identified a small molecule inhibitor 
of β-catenin PMED-1 that blocks β-catenin signaling 
and β-catenin-CBP interactions in multiple cells lines 
(Hep3B, HepG2, Snu-398 and Snu-449), reducing 
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Table 1  Molecular therapies targeting Wnt/β-catenin pathway in hepatocellular carcinoma
Compound Target in vitro Target in vivo
Sorafenib[4] Decrease of TCF/LEF, β-catenin protein levels and Wnt-target genes 
mRNA levels[11]
Decrease tumor volume and increase survival of treated 
animals in HepG2 xenografts in nude mice[11]
sFZD7[66] Block interaction between. FZD and Dvl. Decrease viability of HepG2, 
Hep40 and Huh7 cell lines. Reduced expression of c-Myc, Cyclin 
D1 and Survivin. The effect was potentiated in combination with 
Doxorubicin[66]
Inhibitory effect in Huh7 xenografts[66]
RHPDs[67] Decrease viability of human HCC cell lines (Huh7 and HepG2) through 
degradation of β-catenin and activation of PKCδ in a TP53-independent 
manner[67]
Intratumor injection in SV40-TAg transgenic mouse 
model inhibited HCC progression[67]
BrMC[42] Inhibition of CD133+ LCSCs proliferation, EMT and invasion in 
MHCC97 cell line, and decreased expression of beta-catenin in this 
LCSCs[42]
Inhibition of LCSCs proliferation in Balb/c-nu mice 
xenografts model[42]
SL1122-37[71] 
(Sorafenib derivative)
Inhibitory effect on the proliferation of HCC PLC/PRF/5 cells and the 
formation of angiogenesis of HUVECs[71]
PMED-1[18] Blocks β-catenin and CBP interaction. Suppression of down-stream 
effects in β-catenin signaling in HCC cell lines[18]
Decrease of Wnt signaling in transgenic zebrafish[18]
XAV939[61] Inhibit Tankyrase 1 and 2 inducing degradation of β-catenin by 
stabilization of Axin. Antitumor activity against neuroblastoma[72], 
colon[73], breast[74] and lung[75] cancers, and HCC Decreased nuclear 
β-catenin levels, cell proliferation and colony formation in HepG2 and 
Huh7[76].
Inhibited growth of HepG2 xenograft model of HCC[76]. 
Reduce tumor growth in a conditional APC mutant 
mouse model of colon cancer[73]. Repressed lung cancer 
formation in murine xenograft and transgenic syngeneic 
lung cancer models[75]
CGP049090 Block TCF/LEF and β-catenin interaction. Decrease expression of 
c-myc, Cyclin D1 and Survivin in AML[56], CCL[57], MM[55] and HCC[58,59] 
cells. Induced apoptosis and cell cycle arrest at the G1/S phase.
Inhibitory effect in murine xenograft model of human 
MM[55], HepG2 xenograft model of HCC[58], JVM-3 
subcutaneous xenograft model of CCL[57]
PKF115-854
PKF118-310[54]
FH535[69] Inhibition of the activation of β-catenin-regulated genes in the HCC cell 
lines Huh7, Hep3B and PLC and LCSC. Arrests the cell cycle from G1 
to S-phase[69]
FH535 and Sorafenib 
combination[12]
Synergistic inhibition of LCSC and Huh7 cell lines proliferation. Dose 
dependent inhibition of Cyclin D1, Survivin and Bcl2 expression[12]
LEF/TCF: Lymphoid enhancer factor/T-cell factor; HCC: Hepatocellular carcinoma; LCSCs: Liver cancer stem cells.
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To date, there are two ongoing clinical phase Ⅰ/Ⅱ 
trials using compounds such as PRI-724 and OMP-18R5 
targeting β-catenin signaling pathway for the treatment 
of solid tumors and myeloid malignancies, suggesting 
the potential use of β-catenin inhibition in the treatment 
of HCC.
CONCLUSION
The molecular mechanisms of early liver transformation 
in carcinogenesis are poorly elucidated. Hepatocar-
cinogenesis is a complex multistep process where 
tumors originate from either LCSC or mature hepato-
cytes, and the tissue undergoes chronic inflammation, 
apoptosis, unrestricted proliferation, and permanent 
liver remodeling. An ideal drug regimen would 
eliminate specifically different cancer cells, including 
those with stem cell properties. Combined therapy may 
be necessary to overcome the complex network of 
signaling pathways and ultimately inhibit the signaling 
events that control tumor growth and survival.
So far it remains unclear the specific Wnt-targets 
and downstream signals that contribute to Wnt 
signaling diversity on liver cancer. Evidence suggests 
that this pathway represents an important molecular 
target for HCC therapy as its mutation and activation 
are intrinsically involved with tumor initiation and 
development in at least one-third of HCC. 
The increasing knowledge on adult stem cell 
biology and the general acceptance of the LCSCs 
hypothesis promise to bring revolutionary advances to 
HCC therapy. In this context, no effective compounds 
targeting β-catenin are yet approved for clinical use, 
but further investigation should be granted to identify 
selective inhibitors of this pathway and better define 
their efficacy and toxicity with the ultimate goal to be 
used either alone or in combination to treat patient 
with advanced HCC.
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